🔗 Share this article

Given that the United States undertakes unprecedented revisions to its immunization schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on Covid shots in the global health crisis and has concentrated on possible deaths after Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Public health authorities were set to announce sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of alignment with much of the world with no evidence for public health gain. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US in order to be more like Denmark, a nation with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – usually the domain of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Questions Over Expertise

Høeg has little discernible background in pharmaceutical research, regulation or leadership, which has been customary for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the science of medication creation”, commented Janet Woodcock. “Clearly, she has not acquired the type of experience that previous people who ran CBER have had.”

The drug center has an immense portfolio at the FDA, Woodcock stated.

“The public just zeroes in on the novel medication approvals, but the generic program clears numerous off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and every single one need to be looked after,” she said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative component to the position, which supervises more than 5,000 staff members. “It is a massive administrative position, if you execute it properly,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

In response to questions about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among FDA leaders on vaccines, a representative stated that the “concerns are based on flawed assumptions”.

“This background aligns with the duties of her job,” the representative said, pointing to the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a disputed rapid drug-approval program that reportedly troubled her predecessors. “By what process are these medications being picked for this fast-track system? Who makes the decisions?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards less stringent regulations of all drugs, aside from immunizations.”

Established Past Work on Vaccines

With immunizations, Dr. Høeg has a clearer, if troubling, past, critics observe. She authored a research paper using unverified public submissions to determine the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new administration featured changing guidelines for novel immunizations and ending “unnecessary” immunizations, she said following the vote on a audio program. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from receiving COVID-19 vaccines.

“She is an complete true believer who begins with her preconceived notions and reverse-engineers to fit the data in a extremely misleading, fraudulent fashion,” Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other contrarians, {like|